Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022
Nemaura Medical (Nasdaq: NMRD) will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 on December 7, 2022, at 9:00 AM EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nemaura Medical (Nasdaq: NMRD) will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 on December 7, 2022, at 9:00 AM EST. CEO Dr. Faz Chowdhury will discuss the company's innovative approach to non-invasive wearable diagnostic devices, including its flagship products sugarBEAT® and proBEAT™. These devices target diabetes management and aim to capitalize on the growing health-tech sector, projected to reach $60 billion by 2023. Investors can register for one-on-one meetings during the conference.
Details
News Market Reaction – NMRD
The recorded move for NMRD in the trading session of this news was +0.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 being held on December 6 – 8, 2022.
Presentation Date: December 7, 2022
Time: 9:00am EST
Webcast Link: https://www.webcaster4.com/Webcast/Page/2937/47190
Dr. Chowdhury will be available for one-on-one investor meetings throughout the conference. To attend the conference and request a meeting, register here:
https://planetmicrocapshowcase.com/signup
About Nemaura Medical, Inc.
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program that is currently undergoing pilot studies.
The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly
For more information, please visit www.NemauraMedical.com.
Contact:
Jules Abraham (Media)
CORE IR
917-885-7378
julesa@coreir.com
Bret Shapiro (Investors)
Senior Managing Partner
CORE IR
(561) 479.8566
brets@coreir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.